Conjunctivitis: all 361 studies
Page 4 of 4. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.
- A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen ExtractsStatus unknownNCT01012752Phase 3
- AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated InflammationCompletedNCT01001091Phase 2
- Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese SubjectsCompletedNCT00987272Phase 3
- A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in the Allergen BioCubeCompletedNCT00985075
- A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed SeasonCompletedNCT00982163
- Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis PatientsCompletedNCT00973453Phase 2
- FST-100 Ophthalmic Suspension in Acute Adenoviral ConjunctivitisTerminatedNCT00941486Phase 2
- Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equivalent Units (HEP).CompletedNCT00917488Phase 2
- An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral ConjunctivitisTerminatedNCT00901693Phase 2
- To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen ChallengeWithdrawnNCT00881673Phase 2
- Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic PatientsCompletedNCT00857779Phase 2
- Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic ConjunctivitisCompletedNCT00836485Phase 2
- Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic InflammationCompletedNCT00833495Phase 2
- Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic RhinoconjunctivitisCompletedNCT00833066Phase 1/2
- Long-term Efficacy and Safety Study With Oralgen Grass PollenCompletedNCT00824447Phase 2/3
- Open Label Safety Study of a Birch Pollen Allergen ExtractCompletedNCT00818181Phase 2
- A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen RhinoconjunctivitisStatus unknownNCT00812799Phase 3
- Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite AllergyCompletedNCT00800332Phase 2
- Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With BlepharoconjunctivitisWithdrawnNCT00754949Phase 3
- Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or ConjunctivitisCompletedNCT00732446Phase 3
- Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP UnitsCompletedNCT00718744Phase 2
- Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled AsthmaCompletedNCT00671268Phase 3
- A Comparison of Olopatadine and Fluticasone in Patients With Allergic ConjunctivitisCompletedNCT00655109Phase 4
- Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite AllergyCompletedNCT00652223Phase 1/2
- Efficacy and Safety From a High-dosed Sublingual Grass Pollen PreparationCompletedNCT00623701Phase 3
- Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With BlepharoconjunctivitisCompletedNCT00578955Phase 3
- Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SARCompletedNCT00574379Phase 2
- A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic RhinoconjunctivitisCompletedNCT00574223Phase 2
- Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal KeratoconjunctivitisCompletedNCT00567918Phase 3
- Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal KeratoconjunctivitisCompletedNCT00567762Phase 3
- Efficacy and Safety of Grass Pollen Sublingual ImmunotherapyCompletedNCT00567346Phase 2/3
- Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial ConjunctivitisCompletedNCT00565123Phase 2/3
- Montelukast as a Controller of Atopic SyndromeCompletedNCT00559546Phase 4
- Efficacy-safety Study of Sublingual Immunotherapy With Depigmented-polymerized Pollen Extracts to Treat RhinoconjunctivitisCompletedNCT00550875Phase 2
- Multicenter Trial of Immunotherapy With House Dust Mite AllergoidCompletedNCT00540631Phase 3
- Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT)CompletedNCT00537342Phase 3
- Eye Drop Use in Glaucoma Patients Through Patient Surveys and Video ObservationsCompletedNCT00522600
- Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum PratenseCompletedNCT00501527Phase 2
- Comparison of CL Wear Between Two Allergy DropsWithdrawnNCT00489398Phase 4
- Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic ConjunctivitisCompletedNCT00445874Phase 3
- Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot StudyStatus unknownNCT00443105Phase 2
- Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic ConjunctivitisCompletedNCT00432757Phase 3
- Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic ConjunctivitisCompletedNCT00423007Phase 3
- Twin SUBLIVAC® Grasses Clinical Efficacy StudyCompletedNCT00422149Phase 3
- Systemic Pharmacokinetics of BOL-303224-ACompletedNCT00407589Phase 1
- Mast-Cell Stabilizing Effects of OlopatadineCompletedNCT00389025Phase 4
- A Study Of The Safety And Effectiveness Of A New Treatment For Allergic ConjunctivitisWithdrawnNCT00375596Phase 2
- Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic ConjunctivitisCompletedNCT00364091Phase 3
- Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial ConjunctivitisCompletedNCT00357773Phase 3
- AL-15469A for the Treatment of Bacterial ConjunctivitisCompletedNCT00332293Phase 3
- AL-15469A for the Treatment of Bacterial ConjunctivitisCompletedNCT00331916Phase 3
- Olopatadine 0.2% for the Treatment of Allergic ConjunctivitisCompletedNCT00331500Phase 3
- A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)CompletedNCT00311844Phase 4
- Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008Status unknownNCT00298337Phase 2/3
- Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-GlucanTerminatedNCT00276445Phase 4
- Evaluation of a Rapid Screening Test for Detection of Adenovirus in TearsCompletedNCT00266734Not applicable
- Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic ConjunctivitisCompletedNCT00244543Phase 3
- Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic ConjunctivitisCompletedNCT00241319Phase 3
- Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic ConjunctivitisCompletedNCT00133627Phase 4
- Evaluation and Treatment of Patients With Corneal and External DiseasesCompletedNCT00008541
- Screening for NEI Clinical StudiesCompletedNCT00001734